中泰证券股份有限公司 关于山东博苑医药化学股份有限公司 首次公开发行网下配售限售股上市流通的核查意见 中泰证券股份有限公司（以下简称"中泰证券"或"保荐人"）作为山东博苑医 药化学股份有限公司（以下简称"博苑股份"、"公司"）首次公开发行股票并在创 业板上市的保荐人履行持续督导职责，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指 引第 13 号——保荐业务》等有关规定，对博苑股份首次公开发行网下配售限售 股上市流通事项进行了核查，核查意见如下： 一、首次公开发行网下配售股份概况 根据中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首 次公开发行股票注册的批复》（证监许可[2024]1415 号），公司首次公开发行人民 币普通股（A 股）股票 2,570 万股，并于 2024 年 12 月 11 日在深圳证券交易所 创业板上市。公司首次公开发行股票前总股本为 7,710 万股，首次公开发行股票 完成后公司总股本为 10,280 万股，其中有流通限制或限售安排的股份 ...

关于首次公开发行网下配售限售股份上市流通提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次上市流通的限售股为山东博苑医药化学股份有限公司（以下简称"公 司"）首次公开发行网下配售限售股份； 2、本次申请解除限售股东户数共计 6,023 户,解除限售股份数量为 1,724,702 股，占公司总股本的比例为 1.29%，限售期为自公司股票上市之日起 6 个月； 3、本次限售股上市流通日为 2025 年 6 月 11 日（星期三）。 一、首次公开发行网下配售股份概况 根据中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首 次公开发行股票注册的批复》（证监许可[2024]1415 号），公司首次公开发行 人民币普通股（A 股）股票 2,570 万股，并于 2024 年 12 月 11 日在深圳证券交 易所创业板上市。公司首次公开发行股票前总股本为 7,710 万股，首次公开发行 股票完成后公司总股本为 10,280 万股，其中有流通限制或限售安排的股份数量 为 78,426,694 股，占发行后总股本的比例为 76.29%；无 ...

Group 1: Market Demand for Inorganic Iodides - The market for inorganic iodides is expected to grow significantly due to increasing demand in the pharmaceutical sector, driven by rising healthcare expenditures and an aging population [2] - The demand for contrast agents in medical imaging, particularly in oncology and cardiovascular diagnostics, is projected to increase, contributing to the expansion of the domestic contrast agent market [2] - The rapid development of the global pharmaceutical industry, especially in new drug research and development, is creating a broader market space for high-quality pharmaceutical intermediates, including inorganic iodides [2] Group 2: Applications in Electronics Manufacturing - The domestic production capacity of polarizers is increasing, with polarizers accounting for approximately 10% of the total cost of liquid crystal panels, where iodinated polarizers dominate with an 80%-90% market share [3] - Iodine and potassium iodide are essential raw materials for the production of iodinated polarizers, indicating a strong link between the electronics manufacturing sector and the demand for inorganic iodides [3] Group 3: Company Strategy and Talent Development - The company emphasizes talent development as a core competitive advantage, focusing on innovative recruitment and high-end talent acquisition to enhance overall competitiveness [3] - A dedicated training institution, referred to as the Future Academy, is established to improve employee skills and cultivate young talent, alongside partnerships with external consulting firms for customized training [3] Group 4: Trade Business and Customer Relations - The company's trade business primarily involves the export of refined iodine and other non-self-produced products, catering to the procurement needs of downstream pharmaceutical and chemical clients [3] - This business model not only meets diverse procurement needs but also strengthens strategic cooperation with clients, enhancing customer loyalty and business synergy [3]

证券代码：301617 证券简称：博苑股份 公告编号：2025-031 山东博苑医药化学股份有限公司 1、公司 2024 年度利润分配及资本公积转增股本预案为：以 2024 年 12 月 31 日的总股本 102,800,000 股为基数，拟向全体股东每 10 股派发现金股利人民币 3 元（含税），共计派发现金股利人民币 30,840,000.00 元（含税）。以资本公积 转增股本，向全体股东每 10 股转增 3 股，不送红股，以此计算拟增股本 30,840,000 股，公司注册资本将由人民币 102,800,000.00 元变更为人民币 133,640,000.00 元，公司总股本将由 102,800,000 股增加至 133,640,000 股（最终股数以转增后 中国证券登记结算有限公司深圳分公司计算数据为准）。若利润分配及资本公积 转增股本方案公布后至实施前公司总股本由于可转债转股、股份回购、股权激励 行权、再融资新增股份上市等原因而发生变化的，将按照分配比例不变的原则对 分配总额进行调整，实际分派结果以中国证券登记结算有限责任公司深圳分公司 的结果为准。 2、自公司 2024 年度利润分配及资本公积转 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东博苑医药化学股份有限公司 2024 年年度股东会的 法律意见书 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管 理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务执 业规则》"）等相关法律、行政法规、规章、规范性文件及《山东博苑医药化学股份有限 公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人 资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员资格、 会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案内容及该等议 案所表述 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-030 山东博苑医药化学股份有限公司 2024 年年度股东会决议公告 1、本次股东会无变更、否决提案的情形； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、本次股东会不涉及变更以往股东会已通过的决议。 特别提示： 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间：2025 年 5 月 15 日（星期四）下午 14：30 2、会议召开形式：采取现场投票和网络投票相结合的方式 3、会议召开地点：山东省寿光市侯镇海洋化工园区新海路与大九路路口北 200 米山东博苑医药化学股份有限公司会议室 4、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025 年 5 月 15 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过 深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 15 日 9:15— 15:00 期间的任意时间。 通过现场和网络投票的股东 414 人，代表股份 77,517,674 股，占公司有表 决权股份总 ...

Group 1: Company Overview - Company Name: Shandong Boyuan Pharmaceutical Chemical Co., Ltd. [1] - Stock Code: 301617 [1] - Stock Abbreviation: Boyuan Shares [1] Group 2: Investor Relations Activity - Activity Type: Online collective reception day for listed companies in Shandong [2] - Date of Activity: May 15, 2025 [2] - Time of Activity: 15:00 - 16:30 [2] - Location: P5W Investor Relations Interactive Platform [2] Group 3: Key Personnel - Chairman: Li Chenglin [2] - Vice Chairman and General Manager: Yu Guoqing [2] - Vice General Manager and Board Secretary: Zhang Shanggang [2] - Chief Financial Officer: Sun Teng [2] Group 4: Financial Performance - 2024 Revenue: 132,787.79 million yuan, a year-on-year increase of 29.53% [2] - 2024 Net Profit: 21,312.58 million yuan, a year-on-year increase of 17.04% [2] Group 5: Investor Inquiries - Inquiry about overall performance in 2024 compared to 2023 [2] - Company response regarding performance changes [2]

Group 1: Core Competitive Advantages - The company's core competitive advantages include a circular economy and comprehensive service advantage, utilizing resource integration technology to convert waste into production materials, thereby reducing procurement costs and enhancing customer loyalty through a full industry chain service [2] - The company has a strong technical research and development capability, holding 49 patents (27 invention patents) and has established a provincial-level R&D platform, earning accolades such as "Specialized, Refined, Characteristic, and Innovative 'Little Giant'" and "Shandong Province Manufacturing Industry Single Champion" [2] - The company maintains high product quality and strong customer resources, with major products certified by multiple systems and stable quality, fostering long-term partnerships with well-known clients in niche markets [2] - The company leads the market share in iodides and luminescent materials, participating in the formulation of 1 industry standard and 11 group standards, demonstrating significant industry influence [2] - Compliance in operations has earned customer trust and ensured stable development, with qualifications in safety production and hazardous waste treatment, recognized as an outstanding environmental protection unit [3] Group 2: Financial Performance and Challenges - The company's gross profit margin for 2024 declined compared to the previous year due to rising raw material prices and the continued growth of trade business revenue, which has lower profit margins [3] Group 3: Industry Barriers - The fine chemical industry has high entry barriers, including: - Technical barriers: High technical requirements across multiple fields necessitate long-term R&D investment and experience accumulation, directly affecting product quality, cost control, and environmental compliance [3] - Market barriers: Strict supplier audits from downstream pharmaceutical and chemical industries, along with high switching costs, make it difficult for new entrants to gain market recognition in the short term [3] - Qualification barriers: Production of hazardous chemicals and hazardous waste treatment requires multiple administrative licenses, with increasingly stringent safety and environmental regulations raising compliance thresholds [3] - Financial barriers: Significant funding is required for R&D, equipment upgrades, and capacity expansion, imposing high financial strength requirements on enterprises [3]

关于参加 2025 年山东辖区上市公司投资者 证券代码：301617 证券简称：博苑股份 公告编号：2025-029 山东博苑医药化学股份有限公司 特此公告！ 山东博苑医药化学股份有限公司 董事会 2025 年 5 月 13 日 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山东博苑医药化学股份有限公司（以下 简 称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有 限公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。 届时公司董事长李成林先生；副董事长、总经理于国清先生；财务总监孙腾先生； 副总经理、董事会秘书张山岗先生将在线就公司 2024 年度业绩、公司治理、发 展战略、 经营状况 ...

Group 1: Talent Development and Management - The company emphasizes continuous innovation in recruitment and talent management to align with strategic goals [2][3] - Plans to enhance employee training through the establishment of a dedicated training institution and collaboration with external consulting firms [3] Group 2: Shareholder Returns - For 2024, the company plans to distribute cash dividends of RMB 3 per 10 shares, totaling RMB 30.84 million [4] - Additionally, the company will increase its share capital by 3 shares for every 10 shares held, resulting in an increase of 3,084,000 shares [4] Group 3: Future Development Plans - The company aims to deepen its focus on fine chemicals, particularly in the pharmaceutical sector, while pursuing technological research and industrial exploration [5] - It seeks to become a trusted leader in the industry by aligning with the new development pattern of domestic and international dual circulation [5] Group 4: Market and Product Development - The company is committed to high-end and fine development strategies in the iodide product sector, enhancing R&D investment and market expansion [8] - It aims to optimize market layout and improve brand influence to achieve high-quality growth in iodide products [8] Group 5: Financial Performance - In 2024, the company achieved a revenue of RMB 132.79 million, representing a year-on-year growth of 29.53% [11] - The net profit attributable to shareholders was RMB 21.31 million, reflecting a year-on-year increase of 17.04% [11]